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Introduction
Ulcer formation is a dynamic imbalance between
mucosal aggressive factors and defensive factors. When
the function of defense and repairing factors is less
than that of aggressive factors, mucosal injury worsens,
and finally ulcer formation develops. Ulcer healing and
repair requires a reconstruction of the surface epithe-
lium and underlying connective tissue, including blood
vessels and muscle layers.1 The early phase of mucosal
repair occurs in the absence of cellular proliferation
and is termed restitution or cell migration.2,3 The late
phase of repair of deeper tissue damage involves cell
proliferation as well as angiogenesis of granulation 
tissue to reconstruct the mucosal and submucosal
architecture.1,4 All of these events are controlled and
regulated by cytokines, growth factors, and some
transcription factors that are overexpressed or activated
over injured mucosa or ulcer margins.5–7
In general, re-epithelialization, the migration of
epithelial cells from the wound margin to restore epi-
thelial continuity, is essentially an early process for gas-
trointestinal ulcer healing.2,8,9 Cell migration requires
cytoskeletal rearrangement: actin microfilament assem-
bly, stress fiber and lamelipodia formation, as well as
rearrangement of focal adhesion complex attachments
to the extracellular matrix.10 Growth factors such as
epidermal growth factor (EGF), basic fibroblast
growth factor (bFGF), and hepatocyte growth factor
(HGF), as well as cytokines such as tumor necrosis
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factor (TNF)-α, interleukin (IL)-1β and IL-8, are
reported to activate cell migration.2,7
The expression of TNF-α is increased at ulcer 
sites in rat stomachs; TNF-α is presumably secreted
from macrophages and mononuclear cells.2,11 TNF-α
has been reported to indirectly stimulate cell migration,
partially through the increased production of HGF and
IL-8.2,12 Our previous in vivo studies demonstrated
that dexamethasone, which is a potent corticosteroid,
delayed rat gastric ulcer healing by inhibiting epithelial
cell proliferation and angiogenesis at the ulcer margin.1,4
Our previous in vitro study also showed that dexam-
ethasone inhibited TNF-α-stimulated gastric epithelial
cell proliferation via inhibition of arachidonic acid–
cyclooxygenase (COX)-2 pathway activation.13
In this in vitro study, we evaluated whether 
dexamethasone inhibited TNF-α-stimulated gastric
epithelial cell migration and explored the possible
mechanistic pathways. The findings further explained
the mechanisms of how glucocorticoids delay gastric
ulcer healing.
Methods
All study chemicals were purchased from Sigma
(Sigma Chemical Co., St Louis, MO, USA) unless
otherwise specified. Ten μg TNF-α (human, recombi-
nant) was prepared in 2 mL of 0.01 M phosphate
buffer saline at pH 7.4 containing 0.1% bovine serum
albumin as a stock solution.
Cell culture
The RGM-1 rat gastric mucosal cells were estab-
lished from normal Wistar rats and were a gift from
Dr Hirofumi Matsui of Tsukuba University (RCB-
0876 at Riken Cell Bank, Tsukuba, Japan). RGM-1
cells are epithelial in origin and like mucous epithelial or
mucous neck cells.14,15 Ours were grown in Dulbecco’s
modified Eagle’s medium (DMEM)/F-12 medium
(Gibco BRL, Grand Island, NY, USA) supplemented
with 100U/mL penicillin G, 100μg/mL streptomycin,
and 20% fetal bovine serum (FBS) (Gibco BRL) in an
incubator at 37°C and 5% carbon dioxide.
Cell migration
Cells were seeded in 24-well culture plates and cul-
tured in DMEM/F-12 with 20% FBS until conflu-
ence. After confluence, monolayers of the cells were
starved for 24 hours in the medium containing 1%
FBS. The cells were then pretreated with mitomycin C
(2 μg/mL) for 2 hours before a wound was made to
inhibit cell proliferation.16,17 This dose and treatment
duration of mitomycin almost abolished 10% of FBS-
induced RGM-1 cell proliferation as reflected by a
96% decrease in BrdU (5-bromo-2-deoxy-uridine)
labeling compared to cells incubated with medium
alone at 48 hours.10 An artificial circular wound of
cell-free area 2 mm2 was made in the center of the
monolayer using a plastic blade.16,18 The wounded
monolayer was then cultured in the medium with 
1% FBS in the presence of control, or TNF-α alone 
(2 and 10 ng/mL), or TNF-α (10 ng/mL) with dex-
amethasone (10–8 M and 10–6 M), or dexamethasone
alone (10–8 M and 10–6 M). The size of the cell-free
area was monitored from time 0 to 48 hours using a
digital image processor connected to a microscope
(Nikon, Tokyo, Japan).18 The areas were calculated
with an image-analyzing program (Leica, Cambridge,
England).
Western blot analysis for COX-1, COX-2, 
EGF, and bFGF
After synchronization and pretreatment with mito-
mycin C as described above, cells were treated with
DMEM/F-12 containing 1% FBS and 10 ng/mL
TNF-α in the presence or absence of 10–6 M dexam-
ethasone, or 10–6 M dexamethasone alone for 8 hours.
Cells were then collected in radioimmunoprecipita-
tion assay buffer for Western blot analysis. Following
sonication and centrifugation, protein concentration
was measured using a protein assay kit (BioRad Lab-
oratories, Hercules, CA, USA). Proteins were separated
by SDS-polyacrylamide electrophoresis gel overlaid
with a 10% acrylamide stacking gel, and then transferred
to Hybond C nitrocellulose membranes (Amersham
International Plc., Amersham, UK). Membranes 
were probed with antibodies against COX-1 (1:800),
COX-2 (1:500), EGF (1:500), bFGF (1:500), and 
β-actin (1:2,000) (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) overnight at 4°C and incubated
for 1 hour with secondary antibodies conjugated with
peroxidase. The membrane was developed using an
enhanced chemiluminescence system (Amersham
Biosciences, Piscataway, NJ, USA) and was exposed
to X-ray film (Fuji Photo Film, Tokyo, Japan). Quan-
titation was performed using a densitometer (Scan
Marker III; Microtek, Carson, NV, USA).
Measurement of PGE2 level
After synchronization and pretreatment with mito-
mycin C as described above, cells were treated with
10 ng/mL TNF-α in the presence or absence of dex-
amethasone (10–8 M and 10–6 M), or dexamethasone
(10–6 M) alone for 12 hours. Then, cells were homog-
enized with homogenizing buffer (0.05 M Tris-HCl
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at pH 7.4, 0.1 M NaCl, 0.001 M CaCl2, 1 mg/mL
D-glucose, 28 μM indomethacin to inhibit further
PGE2 formation) for 30 seconds.15 After centrifuga-
tion at 24,148g for 15 minutes at 4°C, the supernatants
were assayed using a commercially available PGE2
enzyme-linked immunosorbent assay (Quantikine;
R&D Systems Inc., Minneapolis, MN, USA). The
assay procedures were in accordance with the protocol
suggested in the kit. Optical densities were determined
with the MRX microplate reader (Dynex Technologies
Inc., Chantilly, VA, USA) at 405 nm. The amount of
protein in the sample was determined by a protein
assay kit, and the intracellular PGE2 level was expressed
as pg/mg protein.15
Statistical analysis
Analytic results are expressed as mean ± standard devi-
ation. There were six samples in each group. Differ-
ences between the means were analyzed with the
Mann-Whitney U test when appropriate. Bonferroni
correction was performed to adjust for the fact that
multiple comparisons were done in each experiment.
A p value < 0.05 was considered to be statistically 
significant.
Results
Effects of TNF-a on cell migration in 
RGM-1 cells
Treatment with TNF-α 2 ng/mL increased RGM-1
cell migration, but there was no significant difference
when compared with control after 12, 24, 36 and 48
hours of treatment. However, treatment with TNF-α
10 ng/mL for 12, 24, 36 and 48 hours significantly
increased cell migration when compared with control
(Figure 1). Thereafter, we chose 10 ng/mL TNF-α as
the working concentration for subsequent experiments
in this study.
Effects of dexamethasone on cell migration in
RGM-1 cells
Dexamethasone treatment alone (10–8 M and 10–6 M)
for 12, 24, 36 and 48 hours did not have a stimula-
tory or inhibitory action on RGM-1 cell migration
when compared with that of control (Figure 2).
Effects of dexamethasone on TNF-a stimulated
RGM-1 cell migration
Dexamethasone treatment (10–8 M and 10–6 M) for
24, 36 and 48 hours significantly inhibited TNF-α
(10 ng/mL) stimulated RGM-1 cell migration when
compared with the TNF-α-treated group. There was
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Figure 1. Effect of TNF-α on cell migration in RGM-1 cells. Cells
were incubated with control or TNF-α (2 ng/mL and 10 ng/mL) for
48 hours. Sizes of the cell-free area were monitored at 0, 12, 24,
36 and 48 hours using a digital image processor connected to a
microscope. The areas were calculated with an image-analyzing
program. Values are mean ± standard deviation for six samples
per group. *p < 0.05 vs. control group.
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Figure 2. Effect of dexamethasone on cell migration in RGM-1
cells. Cells were incubated with control or dexamethasone
(10–8 M and 10–6 M) for 48 hours. Sizes of the cell-free area were
monitored at 0, 12, 24, 36 and 48 hours using a digital image
processor connected to a microscope. Values are mean ± standard
deviation of six samples per group.
no significant difference between the TNF-α plus dex-
amethasone group and the control group (Figure 3).
Effects of TNF-a and dexamethasone on protein
expression of COX-1, COX-2, EGF and bFGF
Treatment with TNF-α 10 ng/mL for 8 hours signif-
icantly increased COX-2 expression when compared
with that of the control group. In contrast, dexam-
ethasone (10–6 M) alone did not decrease COX-2
expression when compared with the control group
(Figure 4). However, the same concentrations of dex-
amethasone (10–6 M) significantly decreased TNF-α-
stimulated COX-2 expression when compared with
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Figure 4. Effect of TNF-α on the protein expression of COX-2 in
RGM-1 cells. Cells were incubated with TNF-α 10 ng/mL in the
absence or presence of dexamethasone (10–8 M and 10–6 M) and
dexamethasone (10–6 M) alone for 8 hours and measured by
Western blot method. Values are mean ± standard deviation of six
samples per group. *p < 0.05 vs. control group; †p < 0.05 vs. TNF-α
treated group.
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Figure 5. Effects of TNF-α and dexamethasone on intracellular
PGE2 level. Cells were incubated with TNF-α 10 ng/mL in the
absence or presence of dexamethasone (10–8 M and 10–6 M) and
dexamethasone 10–6 M alone for 12 hours and measured by
enzyme-linked immunosorbent assay. Values are mean ± standard
deviation of six samples per group. *p < 0.05 vs. control group;
†p < 0.05 vs. TNF-α treated group.
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Figure 3. Effects of dexamethasone on TNF-α stimulated RGM-1
cell migration. Cells were incubated with control, TNF-α
(10 ng/mL), or TNF-α (10 ng/mL) plus dexamethasone (10–8 M or
10–6 M) for 48 hours. Sizes of the cell-free area were monitored
at 0, 12, 24, 36 and 48 hours using a digital image processor
connected to a microscope. Values are mean ± standard deviation
for six samples per group. *p < 0.05 vs. control group; †p < 0.05
vs. TNF-α group. the TNF-α-treated group (Figure 4). There were no
significant differences in the expressions of COX-1,
EGF and bFGF among the different treatment groups,
including the control, TNF-α alone, dexamethasone
alone, and TNF-α plus dexamethasone treated groups
(data not shown).
Effects of TNF-a and dexamethasone on
intracellular PGE2 level
Treatment with TNF-α 10 ng/mL for 12 hours sig-
nificantly increased intracellular PGE2 level when com-
pared with that of the control group (Figure 5). Again,
dexamethasone treatment (10–8 M and 10–6 M) de-
creased PGE2 level in the TNF-α-treated group and
reached a significant difference in the higher concen-
tration group (10–6 M dexamethasone) (Figure 5).
Discussion
Our study demonstrated that TNF-α increased COX-2
expression and PGE2 formation, and stimulated rat
gastric epithelial (RGM-1) cell migration. Dexametha-
sone inhibited TNF-α-stimulated RGM-1 cell migra-
tion, which was associated with a decrease in COX-2
expression and PGE2 formation. These findings further
explain the reasons and mechanisms for how gluco-
corticoids delay gastric ulcer healing.
Our previous study showed that TNF-α (2 and
10 ng/mL) and dexamethasone (10–8 M and 10–6 M)
alone did not alter cell viability (by MTT [3-(4,5-
dimethyl-thiazol-2yl)-2,5-diphenyltetrazolium bro-
mide] reduction method) or induce RGM-1 cell
apoptosis (by DNA laddering), respectively.13 That
study also showed that TNF-α, which was overex-
pressed in the gastric ulcer margin,11 played a positive
role in RGM-1 cell proliferation via activating the
arachidonic acid–COX-2 pathway, which is important
for mucosal defense and ulcer healing.1,13 The current
study showed that TNF-α at the same concentration
(10 ng/mL) significantly stimulated COX-2 expres-
sion and PGE2 formation, and increased RGM-1 cell
migration, which is the initial step in mucosal repair
before cellular proliferation. In fact, activation of the
COX-2 pathway is essential for cell migration.19,20
TNF-α also upregulated the production of HGF and
IL-8, which promoted cell migration.2,12,20
This study also revealed that dexamethasone
inhibited TNF-α-stimulated COX-2 expression and
PGE2 formation, and inhibited TNF-α-stimulated
RGM-1 cell migration. It was interesting to find that
dexamethasone alone did not have an inhibitory
action on basal RGM-1 cell migration when com-
pared with that of control, but did have an inhibitory
action on TNF-α-stimulated cell migration when
compared with the TNF-α-treated group. The find-
ings are in agreement with data showing that COX-2
expression and intracellular PGE2 levels were compa-
rable between the control group and the dexametha-
sone (10–6 M) group, although COX-2 expression
and PGE2 synthesis were a little weaker in the dexam-
ethasone group than in the control group. Further
study is needed to clarify why dexamethasone alone
did not have an inhibitory action on basal RGM-1
cell migration.
The concentrations of dexamethasone (10–8 M
and 10–6 M) we used in this study are similar to the
pharmacologic concentration that is found in the
plasma of patients treated with dexamethasone.20,21
Putting together the findings of our previous studies
and the current study, we demonstrated that dexam-
ethasone inhibited EGF, bFGF, TNF-α-stimulated
RGM-1 cell proliferation, and TNF-α-stimulated RGM-
1 cell migration.13,15,22 We also found that dexam-
ethasone inhibited EGF, bFGF, and TNF-α-stimulated
COX-2 expression. These findings also support our
previous studies that showed that dexamethasone
delayed rat gastric ulcer healing via inhibition of epithe-
lial cell proliferation in ulcer margins and angiogenesis
of ulcer base.1,4
In conclusion, TNF-α increased COX-2 expres-
sion and PGE2 formation, and stimulated rat gastric
epithelial (RGM-1) cell migration. Dexamethasone
inhibited TNF-α-stimulated RGM-1 cell migration,
which was associated with a decrease in COX-2
expression and PGE2 formation.
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